

Antimicrobial treatment of *Erysipelatoclostridium ramosum* invasive infections: a systematic review

Milos N. Milosavljevic¹, Marina Kostic¹, Jasmina Milovanovic¹, Radica Zivkovic Zaric¹, Milorad Stojadinovic^{1,2}, Slobodan M. Jankovic¹, Srdjan M. Stefanovic³

ABSTRACT

The aim of this systematic review was to determine the causal role of *Erysipelatoclostridium ramosum* in specific invasive infections in humans, and to assess the clinical outcome of antibiotic therapy used to treat them. Several electronic databases were systematically searched for clinical trials, observational studies or individual cases on patients of any age and gender with a systemic inflammatory response syndrome (SIRS) due to *E. ramosum* isolated from body fluids or tissues in which it is not normally present. Only reports identifying *E. ramosum* as the only microorganism isolated from a patient with SIRS were included. This systematic review included 15 studies reporting 19 individual cases in which *E. ramosum* caused invasive infections in various tissues, mainly in immunocompromised patients. *E. ramosum* was most often isolated by blood cultures and identified by specific biochemical tests. Severe infections caused by *E. ramosum* were in most cases effectively treated with antibiotics, except in two patients, one of whom died. More than one isolate of *E. ramosum* exhibited 100% susceptibility to metronidazole, amoxicillin/clavulanate and piperacillin/tazobactam. On the other hand, individual resistance of this bacterium to penicillin, ciprofloxacin, clindamycin, imipenem and ertapenem was reported. This systematic review confirmed the clinical relevance of *E. ramosum* as a cause of a number of severe infections mainly in immunocompromised inpatients. Metronidazole and meropenem appear to be the antibiotics of choice that should be used in combination or as monotherapy to treat *E. ramosum* infections, depending on the type and severity of the infection.

KEYWORDS: *Erysipelatoclostridium ramosum*. Gram-positive bacillus. Invasive infection. Antibiotic treatment. Systematic review.

INTRODUCTION

The recently revised genome-based bacterial taxonomy classified *Erysipelatoclostridium ramosum* (genus *Erysipelatoclostridium*) into the family *Erysipelatoclostridiaceae*, along with other strains of the phylogenetic clostridium VIII species¹. Previously, this Gram-positive, non-mobile, spore-forming anaerobic bacillus was known for a long time as *Clostridium ramosum*, while it was called *Bacillus ramosum* and *Ramibacterium ramosum* during the first several decades since its discovery in 1898². *Erysipelatoclostridium ramosum* (*E. ramosum*) belongs to the human gut commensal microbiota, though some strains have the ability to produce IgA1 and IgA2 proteases, thus increasing the host susceptibility to opportunistic bacterial invasion by translocation across the intestinal mucosa³. This particularly affects children under the age of five and immunocompromised elderly people who,

¹University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacology and Toxicology, Kragujevac, Serbia

²University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia

³University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Kragujevac, Serbia

Correspondence to: Milos N. Milosavljevic
Faculty of Medical Sciences, Department of Pharmacology and Toxicology, Svetozara Markovica 69, 34000, Kragujevac, Serbia
Tel: +38 16 69047886

E-mail: milosavljevicmilos91@gmail.com

Received: 26 January 2021

Accepted: 1 March 2021

although rarely, could develop invasive infections^{4,5}. Due to the many difficulties to properly grow *E. ramosum* in culture and perform its identification by routine microbiological techniques, the incidence of both, possible endogenous and exogenous infections caused by *E. ramosum* is considered underestimated in the real-world clinical practice. The use of modern diagnostic techniques, such as mass spectrometry, has shown that various anaerobic gram-positive bacteria, which are not considered so common, may cause brain abscesses⁶. Invasive infections such as bacteremia⁵, septic arthritis⁷, septic pseudoarthrosis⁸, osteomyelitis⁹, cerebellar abscess¹⁰, lung abscess¹¹, Fournier's gangrene¹², gas gangrene¹³, spondylodiscitis¹⁴, pseudomembranous colitis¹⁵, septic arteria emboli¹⁶ among others, might be associated with a high risk of death.

To our best knowledge, no evidence-based guidelines have been proposed to date to support adequate antibiotic therapy for *Erysipelatoclostridium ramosum* infections. Published literature has mostly reported individual cases suggesting certain antibiotics for the treatment of these infections based on *in vitro* susceptibility testing^{4,5,7,14,17,18}. *E. ramosum* shows excellent susceptibility to piperacillin-tazobactam, amoxicillin/clavulanate, ampicillin/sulbactam, imipenem, meropenem, metronidazole, vancomycin and chloramphenicol. Sensitivity to penicillin and cephalosporins is variable, most likely due to the production of β -lactamases by some *E. ramosum* strains^{5,14}. Similarly, discordant results related to clindamycin sensitivity have been reported^{5,12}. There is probably an intrinsic resistance to aminoglycosides, fluoroquinolones, rifampin and most of tetracyclines^{5,14,19}. In addition, the doses and duration of antibiotic therapy can also vary significantly. Considering all of the above, there is an unmet clinical need to create some kind of guidance for antibiotic treatment of invasive *E. ramosum* infections that could help physicians to address this rare but potentially serious problem in clinical practice.

Therefore, the goal of the present systematic review was to determine the causal role of *E. ramosum* in specific invasive infections in humans and to assess the clinical outcomes of antibiotic therapy used to treat them.

MATERIALS AND METHODS

Reports from clinical trials, observational studies or individual cases including case reports and case series on patients of any age and gender presenting with systemic inflammatory response syndrome (SIRS) due to *E. ramosum* isolated from body fluids or tissues in which it is not normally present and identified by one or more of the following diagnostic methods: conventional techniques such as colony morphology, standardized biochemical reactions, gas-liquid

chromatography, commercial anaerobe kits, among others, as well as more sophisticated and accurate methods, such as Matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) and species-specific polymerase chain reaction (PCR) for *E. ramosum*¹⁹, were accepted for inclusion in this systematic review. Most importantly, only reports identifying *E. ramosum* as the only microorganism isolated from a patient with SIRS were included. On the other hand, reports published on the cases of *E. ramosum* infections mentioned in review articles, cases of *E. ramosum* infections in non-human species and cases with incomplete data were excluded from this review.

The strategy of finding relevant published articles was focused on the search of the following electronic database: Medline (PubMed), Scopus, Ebsco database (Discovery Service), Google Scholar, Cochrane database of published clinical trials – Central (Wiley Online Library), ClinicalTrials.gov (U.S. National Library of Medicine), and SCIndex (Serbian Citation Index). The search of these electronic databases covered the last 50 years (from 1970 to May 5, 2020). Six authors (SS, MM, JM, MK, RZZ, and MS) performed the search independently. The researcher MM developed the most comprehensive search of the Medline database: (((“bacillus”[MeSH Terms] OR “bacillus”[All Fields]) AND ramosum[All Fields]) OR (Ramibacterium[All Fields] AND ramosum[All Fields]) OR (“clostridium”[MeSH Terms] OR “clostridium”[All Fields]) AND ramosum[All Fields]) OR (Erysipelatoclostridium[All Fields] AND ramosum[All Fields])) AND ((invasive[All Fields] AND (“infection”[MeSH Terms] OR “infection”[All Fields] OR “infections”[All Fields])) OR (“bacteraemia”[All Fields] OR “bacteremia”[MeSH Terms] OR “bacteremia”[All Fields]) OR (“arthritis, infectious”[MeSH Terms] OR (“arthritis”[All Fields] AND “infectious”[All Fields]) OR “infectious arthritis”[All Fields] OR (“septic”[All Fields] AND “arthritis”[All Fields]) OR “septic arthritis”[All Fields]) OR (septic[All Fields] AND (“pseudarthrosis”[MeSH Terms] OR “pseudarthrosis”[All Fields] OR “pseudoarthrosis”[All Fields])) OR (“peritonitis”[MeSH Terms] OR “peritonitis”[All Fields]) OR (“cerebellum”[MeSH Terms] OR “cerebellum”[All Fields] OR “cerebellar”[All Fields]) AND (“abscess”[MeSH Terms] OR “abscess”[All Fields])) OR (“brain abscess”[MeSH Terms] OR (“brain”[All Fields] AND “abscess”[All Fields]) OR “brain abscess”[All Fields]) OR (“lung abscess”[MeSH Terms] OR (“lung”[All Fields] AND “abscess”[All Fields]) OR “lung abscess”[All Fields]) OR (“gas gangrene”[MeSH Terms] OR (“gas”[All Fields] AND “gangrene”[All Fields]) OR “gas gangrene”[All Fields]) OR (“fournier gangrene”[MeSH Terms] OR (“fournier”[All Fields] AND “gangrene”[All Fields]) OR

“fournier gangrene”[All Fields] OR (“fournier’s”[All Fields] AND “gangrene”[All Fields]) OR “fournier’s gangrene”[All Fields] OR (“discitis”[MeSH Terms] OR “discitis”[All Fields] OR “spondylodiscitis”[All Fields]) OR (“anaemia”[All Fields] OR “anemia”[MeSH Terms] OR “anemia”[All Fields]) OR (“osteomyelitis”[MeSH Terms] OR “osteomyelitis”[All Fields]) OR (“sepsis”[MeSH Terms] OR “sepsis”[All Fields]) OR (“enterocolitis, pseudomembranous”[MeSH Terms] OR (“enterocolitis”[All Fields] AND “pseudomembranous”[All Fields]) OR “pseudomembranous enterocolitis”[All Fields] OR (“pseudomembranous”[All Fields] AND “colitis”[All Fields]) OR “pseudomembranous colitis”[All Fields])). No restrictions were made regarding the format, language or date of publication. The “snowball” method was also used to search for additional similar articles using references and key words of the retrieved papers.

Initially, the eligibility of retrieved studies was screened based on titles and abstracts, by six authors (SS, MM, JM, MK, RZZ, and MS) independently. In cases in which it was not possible to assess whether the study fully corresponded to the research topic on the basis of abstracts and titles, the full-length article was retrieved and analyzed. Articles were included in the review if all authors (SS, MM, SJ, JM, MK, RZZ and MS) agreed that eligibility criteria were met. If the reviewers had different opinions on the suitability of the study for inclusion, the matter was resolved by the senior author (SJ).

The data extracted from the included papers were entered in Excel table and assessed for: (1) Publication ID, (2) Report ID, (3) Review author initials, (4) Citation and contact details, (5) Eligibility for review, (6) Study design, (7) Total study duration, (8) Risk of bias, if applicable (randomization if any, sequence generation, allocation sequence concealment, blinding, unequal loss of participants from a study, and other concerns about bias), (9) Total number of patients, (10) Age of patients, (11) Gender of patients, (12) Setting, (13) Country, (14) Presence of comorbidities or underlying immunocompromising acute or chronic conditions, such as prior antibiotic use and/or surgery or traumatic injury and/or diabetes mellitus and/or cancer and/or renal or liver failure, among others, (15) Site of isolation of the bacterium (body fluid or tissue), (16) Sampling method, (17) Method of *E. ramosum* identification (biochemical methods and/or MALDI TOF and/or 16S RNA sequencing or other routine microbiological techniques for detecting specific anaerobes, if used), (18) Maximal level of C-reactive protein (CRP) during the infection, (19) Maximal level of procalcitonin in serum during the infection, (20) Maximal white cells count (WBC) during the infection [*leucopenia,

as a potential marker of SIRS was also recorded (if it had been reported)], (21) Presence of clinical signs of systemic infection (related to body temperature, heart rate, blood pressure and respiratory rate), (22) Additional morphological, radiography and/or endoscopic diagnostic methods which confirmed the invasiveness of infection (findings of radiographic imaging procedures such as X-ray or ultrasound scans or computerized tomography scans or magnetic resonance imaging examinations), (23) Altered specific hematological and biochemical laboratory parameters that suggested infections of organs/tissues, (24) Confirmed postoperative infection, (25) Antibiotic regimen used, (26) Cure rate and mortality after antibiotic treatment, (27) Adverse events rate, and (28) *In vitro* susceptibility of *E. ramosum* to antibiotics. The data were extracted by three investigators independently (MM, MK, and RZZ) and then the comparison of the three tables was made by another two investigators (SS and SJ), who produced the final extraction table.

Four researchers (SS, MM, JM and MS) assessed the risk of bias independently for each selected study separately (in accordance with their methodological approaches), while analyzing the following relevant potential sources: attrition bias, selection bias, information bias, and outcome (selective) reporting bias. The final assessment was provided by a senior investigator (SJ). The outcome reporting bias was assessed by determining the proportion of reported target results. In addition, the included studies were arranged according to their geographical distribution, and then the uniformity of the tabulation was estimated.

Then, relevant outcomes were measured in this systematic review: total study duration, age of patients, total number of patients, and maximal serum level of CRP, maximal serum level of procalcitonin and maximal WBC count during the infection as continuous outcomes, while the gender of patients, presence of comorbidities, methods of *E. ramosum* identification, morphological diagnosis confirming the invasiveness of infection, altered specific hematological and biochemical laboratory parameters that suggested infections of organs/tissues, confirmed postoperative infection, type of invasive infections caused by *E. ramosum*, type and dose regimen of antibiotics used to treat *E. ramosum* infection, outcomes of antibiotic treatment (cure rate and mortality), adverse events rate, and sensitivity/resistance rate of *E. ramosum* to antibiotics, were chosen as categorical outcomes. Individual participants from the included studies were identified to be a unit of analysis. Prior to this analysis, outcomes based on observation data were ascertained only once.

The problem of addressing the missing data included the following: (i) the authors of the original paper were

directly requested to provide it; (ii) a reference to the results of retrieved papers if disclosed on ClinicalTrial.gov; and (iii) the Discussion section commented on the impact of the missing data on the final results of this review. The assessment of the presence of heterogeneity was not applicable to this type of systematic review.

Standard methods of descriptive statistics were used to describe and summarize the results on a small sample: median and interquartile range (IQR) for continuous variables; number and percentage for categorical variables.

RESULTS

Literature search results are summarized in [Figure 1](#). The final analysis covered a total of 15 studies that met the inclusion criteria. Among them, there were 11 case reports and 4 case series that reported a total of 19 individual cases. The median age of the subjects with reported invasive infection caused by *E. ramosum* was 66 (IQR 26, 74), with the oldest being 91 years old, while the two youngest were 3 years and 6 months old, respectively. A little more than half of the cases were males (11/19 or 57.9%). Various types of cancers were the most commonly reported comorbidities/immunocompromising conditions (4/19 or 21%), followed by chronic renal failure treated

under dialysis (2/19 or 10.5%), diabetes mellitus (2/19 or 10.5%) and infected deep-pressure ulcers (2/19 or 10.5%); other morbid conditions were reported sporadically ([Table 1](#)). Two children (10.5% of the total number of cases) with otitis media were identified as being predisposed to *E. ramosum* invasive infections, of whom the older child (5 years old) presented with a chronic suppurative form, a cerebellar abscess that was an intracranial complication ([Table 1](#)). *E. ramosum* as the causative etiological agent in postoperative infections was reported in three patients (15.8%) ([Table 1](#)). [Figure 2](#) depicts the geographical distribution of cases involved in this systematic review. Most reported cases were from the USA (6/19 or 31.6%), followed by Spain (3/19 or 15.8%), Switzerland (2/19 or 10.5%), France (2/19 or 0.5%) and Korea (2/19 or 10.5%). Japan, India, Saudi Arabia and Turkey reported only one case each (5.3%). All patients involved were treated exclusively in hospitals. A case series lasting 17 years⁴ was the longest study included in the analysis. In addition to an overview of individual cases, [Table 1](#) also shows an assessment of the risk of bias for each included study.

Blood culture was the most commonly used test used to detect *E. ramosum* (10/19 or 52.6%) ([Table 1](#)). *E. ramosum* as the cause of infection was most often initially identified exclusively by biochemical methods (7/19 or 36.8%), while




Figure 1 - Selection of studies.

Table 1 - Overview of reported *E. ramosum* cases.

Study	Study design	Attrition/ Selective reporting bias	Age (years)	Gender	Comorbidity or immuno- compromised condition	Site of isolation of <i>E. ramosum</i>	Type of infection	Antibiotic used for therapy	Dose of antibiotic used for therapy	Duration of antibiotic therapy	Outcomes of antibiotic treatment
Alcaide-Vargas <i>et al.</i> ¹⁵	Case report	Low/High	79	F	Previous antibiotic treatment (beta- lactam and subsequent fluoroquinolone), older age	Blood	Pseudomembraneous colitis and bacteremia	Metronidazole	Not reported	15 days	Clinical improvement
Brasha <i>et al.</i> ²⁴	Case report	Low/Low	37	F	Large uterine fibroid myoma	Pus from uterine fibroid tissue	Postpartum pyomyoma	Pipracillin/ tazobactam (in hospital) Amoxicillin/clavulanic acid (at discharge)	Pipracillin/ tazobactam 4.5 (4/0.5) g / 8h Amoxicillin/ clavulanic acid for 500 /125) mg / 8h 14 days	Pipracillin/ tazobactam for at least 5 days Amoxicillin/ clavulanic acid for 14 days	Clinical improvement
Brook ⁴	Case series	Low/Unclear Low/Unclear* *selection/ information bias	3.5	F	Unknown disease of gastrointestinal tract	Blood	Bloodstream infection	Penicillin	Not reported	Not reported	Complete recovery
Brook ⁴	Case series	Low/Unclear Low/Unclear* *selection/ information bias	3.5	M	Young preschooler child	Middle ear	Acute otitis media	Amoxicillin	Not reported	Not reported	Complete recovery
Dayha <i>et al.</i> ⁹	Case report	Low/Unclear	26	M	Traumatic injury (open tibial shaft fracture treated with intramedullary interlocking nail fixation)	Blood and postoperative wound	Osteomyelitis	Vancomycin plus tigecycline	Not reported	12 weeks	Failure of antibiotic treatment led to amputation
García-Jiménez <i>et al.</i> ⁷	Case series	Low/Low High/Unclear* *selection/ information bias	62	F	Rheumatoid arthritis with implanted prosthetic joint	Joint fluid and intraoperative cultures	Septic arthritis	Initially Meropenem + metronidazole, switched to IV penicillin + clindamycin + metronidazole	Not reported	Meropenem+ Metronidazole 6 weeks; IV penicillin+ Clindamycin (unknown duration) plus Metronidazole for 3 months	Clinical improvement
García-Jiménez <i>et al.</i> ⁷	Case series	Low/Low High/Unclear* *selection/ information bias	53	M	Chronic renal failure/ hemodialysis	Blood and abscess aspirate	Septic arthritis	Initially ampicillin + Gentamycin, switched to amoxicillin- clavulanate	Not reported	Ampicillin+ Gentamycin 6 weeks; Amoxicillin- clavulanate 6 weeks	Clinical improvement
Gerber <i>et al.</i> ¹⁷	Case report	Low/High	74	M	Alcoholic liver cirrhosis with hepatorenal syndrome treated initially with hemo- and peritoneal dialysis, older age	Peritoneal fluid	Peritonitis leading to sepsis	Initially IP ceftazolin + Ceftazidime, switched to IV Ceftazidime + Vancomycin (ET was not effective), switched to comfort care	Not reported	Not reported	Unclear

Table 1 - Overview of reported *E. ramosum* cases (cont.).

Author	Case series	Age	Sex	Hematological cancer, older age	Blood	Bloodstream infection	Cefepime + Metronidazole (ET)	Not reported	Not reported	Clinical improvement
Gollapudi <i>et al.</i> ²⁰	Low/Unclear High/Unclear* **selection/ information bias	66	F	Hematological cancer, older age	Blood	Bloodstream infection	Cefepime + Metronidazole (ET)	Not reported	Not reported	Clinical improvement
Gollapudi <i>et al.</i> ²⁰	Low/Unclear High/Unclear* **selection/ information bias	79	M	Hematological cancer, older age	Blood	Bloodstream infection	Ceftazidime + Metronidazole (ET)	Not reported	Not reported	Death
Kozaki <i>et al.</i> ¹⁸	Low/Low	73	M	Diabetes mellitus, older age	Aortic wall and surrounding tissue samples during surgery	Infected thoracic aortic aneurysm	Initially meropenem+ Metronidazole, switched to oral minocycline	Meropenem 0.5g/6h, Metronidazole 0.5g/8h	Meropenem+ Metronidazole 7 days; Immunoglobulin 3 days; Minocycline not reported	Complete recovery
Lavigne <i>et al.</i> ¹⁴	Low/Low	74	M	Prostatic adenoma, older age	Diskal puncture aspirate	Spondylodiscitis	Initially, IV Amoxicillin + p.o. Metronidazole, switched to oral amoxicilline and metronidazole at discharge	IV and oral amoxicillin 2 g/8h, Metronidazole 0.5g/8h	Oral amoxicillin plus Metronidazole 4 weeks	Clinical improvement
Lim <i>et al.</i> ²¹	Low/Low High/Unclear* *selection and information bias	89	F	Colon cancer, older age	Blood	Bloodstream infection	Initially, ceftriaxone, switched to tigecycline	Not reported	Ceftriaxone 2 days; Tigecycline- not reported	Clinical improvement
Lim <i>et al.</i> ²¹	Low/Low High/Unclear* *selection and information bias	70	M	Infected pressure ulcers, older age	Blood	Bloodstream infection	Meropenem plus teicoplanin	Not reported	Unclear	Clinical improvement
Lorleac'h <i>et al.</i> ²⁶	Low/Unclear	72	M	Bioprosthetic aortic valve replacement due to aortic stenosis, older age	Blood	Endocarditis	Amoxicillin	Not reported	Not reported	Clinical improvement
Mohandas <i>et al.</i> ²²	Low/Unclear	91	F	Arterial hypertension, diabetes mellitus, infected pressure ulcers, older age	Blood	Bloodstream infection and osteomyelitis	Ampicillin-sulbactam+ gentamicin	Not reported	Not reported	Clinical improvement
Set <i>et al.</i> ¹⁰	Low/Unclear	5	M	Chronic suppurative otitis media in a young preschooler child	Cerebellar abscess with pus	Cerebellar abscess	Ampicillin + Chloramphenicol + Metronidazole	Not reported	Not reported	Clinical improvement
Turocglu <i>et al.</i> ²⁵	Low/Unclear	7	M	Invasive diagnostic and therapeutic procedures due to pleural empyema, brain hydatid disease	Hydatid cyst fluid	Infected intracranial hydatid cyst	Meropenem	Not reported	28 days	Clinical improvement
Zakham <i>et al.</i> ⁸	Low/Low	26	F	Ewing sarcoma	Bone and tissue fragment	Septic pseudoarthrosis	Clindamycin	0.6g/8h	8 months	Complete recovery

M = male; F = female; IP = intraperitoneal; IV = intravenous; ET = empirical therapy



Figure 2 - Geographical distribution of *Erysipelatoclostridium ramosum* studies. Countries in which *E. ramosum* was isolated are shaded in gray. Source: Wikipedia Commons³⁰.

additional confirmation using 16S rRNA gene sequencing was carried out in three cases (15.8%) cases. Combination of these two methods with MALDI-TOF mass spectrometry (i.e. a triple diagnostic method) was used in three (15.8%) cases. The 16S rRNA sequencing, as the only method for the identification of *E. ramosum*, was performed in two patients (10.5%), as was the use of gas-liquid chromatography alone (2/19 or 10.5%). Finally, in two cases (10.5%), the method of bacterial identification was not specified.

Thirteen patients (68.4%) had signs and symptoms of systemic infection, with fever being the most common symptom (12/19 or 63.2%). None of the potential indicators of systemic inflammatory response to infection, such as fever, tachycardia, tachypnea and hypotension, were reported in six patients (31.6%) included in our study. The level of CRP during infection was measured in only four cases, with the following maximal findings: 51, 166, 278.31 and 31.4 mg/L (median 108.5, IQR 36.3, 250.2). In addition, in five cases, the maximum WBC count at any time during infection was reported, with the following measured values: $11.1 \times 10^9/L$, $11.6 \times 10^9/L$, $12.0 \times 10^9/L$, $12.5 \times 10^9/L$ and $16.9 \times 10^9/L$ (median $12.0 \times 10^9/L$, IQR $11.4 \times 10^9/L$, $14.7 \times 10^9/L$). The maximum level of procalcitonin was not reported in any of the patients included in our study. The additional morphological, radiographic and/or endoscopic diagnostic procedures were performed in more than a half of the cases (11/19 or 57.9%), and the following diagnoses were confirmed: septic arthritis and osteomyelitis in two cases each (10.5%), while pseudomembranous colitis, spondylodiscitis, pyomyoma, endocarditis, cerebellar abscess, infection of intracranial hydatid cyst and infection of thoracic aortic aneurysm in one case each (5.3%). Altered laboratory findings indicating a specific organ/

tissue infection were reported in two cases: a patient under peritoneal dialysis and presenting with peritonitis with more than $7,000/mm^3$ WBC (with predominance of neutrophils) measured in the dialysate, and in patient with septic arthritis, $95,000/mm^3$ WBC (94% of neutrophils) measured in the joint fluid. Altogether, *E. ramosum* was most often found to be a causative agent of bloodstream infections (6/19 or 31.6%) (Table 1).

Antimicrobial susceptibility testing of *E. ramosum* was performed in eight patients (42.1%), and the summarized susceptibility pattern of these isolates is depicted in Figure 3. Almost two thirds of all isolates (5/8 or 62.5%), or isolates collected from five of the total number of 19 included cases, were tested for susceptibility to metronidazole and penicillin, and the sensitivity of *E. ramosum* to metronidazole was confirmed in all five cases (susceptibility of 100%), while in one patient this bacterium was resistant to penicillin (susceptibility of 80%). In the studies in which more than two isolates were reported to have being tested for the susceptibility to specific antibiotics, they were all susceptible to amoxicillin/clavulanate (4/12 or 33.3%) and piperacillin/tazobactam (3/12 or 25%). Finally, in addition to penicillin, individual cases of *E. ramosum* resistant to clindamycin, ciprofloxacin, imipenem and ertapenem were also reported.

Treatment of *E. ramosum* invasive infections in a majority of the patients (12/19 or 63.2%) comprised more than one antimicrobial drug, while mono antibiotic therapy was used in seven cases (36.8%). Metronidazole was the most commonly used antibiotic (7/19 or 36.8%), followed by meropenem (5/19 or 26.3%), and amoxicillin (4/19 or 21%) (Figure 4). In most patients (12/19 or 63.2%) a relevant clinical improvement was reported after antibiotic




Figure 3 - Susceptibility of *E. ramosum* to antibiotics.




Figure 4 - Antibiotics used for treatment of *E. ramosum* infections.

therapy, while four patients (21%) experienced a complete recovery. A fatal outcome was reported in one patient with bacteremia, and in one patient with osteomyelitis that underwent amputation due to the antibiotic therapy

failure. Finally, the antibiotic therapy effectiveness was not completely clear in one patient with peritonitis. Adverse effects of the applied antibiotics were reported only for clindamycin, which was discontinued in a patient with

pseudoarthritis after eight months of continuous therapy due to the occurrence of serious gastrointestinal side effects. The antibiotic treatment used in individual patients is shown in Table 1.

DISCUSSION

This systematic review confirmed the clinical relevance of *E. ramosum* as a cause of various severe infections mainly in immunocompromised inpatients. These opportunistic infections, of which bloodstream infections were the most commonly reported, affected both, children and adults, with a predilection for elderly patients. The most common chronic underlying diseases associated with immunodeficiency were different types of cancer, diabetes mellitus and end-stage renal disease treated under hemodialysis and/or peritoneal dialysis, similarly to the emergence of infections by other anaerobic pathogens⁶. *E. ramosum* was most often isolated from blood culture and identified by specific biochemical tests, in a little more than 50% of the total number of patients and almost 40% of all cases, respectively. In one-sixth of all cases, novel sophisticated molecular techniques, such as MALDI-TOF mass spectrometry and 16S rRNA gene sequencing, were used to confirm the identification of isolated *E. ramosum*. This bacterial species was also recovered from different infection sites, depending on the infected tissue. Serious infections caused by *E. ramosum* were in most cases effectively treated with antibiotics, except in two patients, one of whom died. More than one isolate of *E. ramosum* exhibited 100% of susceptibility to metronidazole, amoxicillin/clavulanate and piperacillin/tazobactam, contrasting with individual strains of this bacterium resistant to penicillin, ciprofloxacin, clindamycin, imipenem and ertapenem that were also reported. Along with metronidazole, meropenem was the most commonly used highly effective antibiotic, which was given as part of initial empirical antibiotic therapy.

Being a normal resident of the human intestinal flora, *E. ramosum* plays only in rare occasions a pathogenic role, leading to invasive infections most commonly in older adults with any type or degree of compromised immune system. Our review included reports of various of these infections that could be reliably associated with immunosuppressive conditions, such as: (i) septicemia in patients with hematological cancers²⁰ or colon carcinoma²¹ or in a frail elderly, a bedridden patient presenting with multiple severely infected pressure ulcers²¹; (ii) septicemia and osteomyelitis²² or infected thoracic aortic aneurysm¹⁸ in patients with diabetes mellitus; (iii) septic arthritis in a patient with rheumatoid arthritis after prosthetic joint replacement or in a case of chronic renal failure under

hemodialysis⁷; (iv) peritonitis followed by sepsis in patient with hepatorenal syndrome under hemo- and peritoneal dialysis¹⁷ and septic pseudoarthrosis in a case of Ewing's sarcoma⁸. Interestingly, similar to the best known and more important human opportunistic pathogen from the *Clostridia* class, i.e. *Clostridium difficile*²³, *E. ramosum* was also found to be a causative agent of pseudomembranous colitis and bacteremia, in an advanced aged patient after a previous use of wide spectrum antibiotics (fluoroquinolones and beta-lactams)¹⁵. In addition, *E. ramosum* caused an acute middle ear infection⁴ leading to an intracranial abscess as a complication of a suppurative chronic otitis media¹⁰ in a young child. As mentioned earlier, these two target populations of patients have long been recognized in terms of susceptibility to *E. ramosum* infections^{4,5}. A high risk for *E. ramosum* infection is likely to be associated with underdevelopment and dysfunction of the intestinal mucosal barrier in young children and immunodeficient adults/elderly patients, that enable the unique virulence factors (IgA proteases) of this commensal anaerobic bacterium to help invading the host and cause infection at various locations, scaping the host's defense⁵. However, rare reports described *E. ramosum* as the causal agent of invasive infections in apparently immunocompetent individuals with complicated benign disorders or with indwelling medical devices due to sepsis after bowel perforation, unknown benign gastrointestinal disease in a preschool child⁴, postpartum pyomyoma²⁴, spondylodiscitis in an older patient with benign prostatic hyperplasia¹⁴, secondary infection in a hydatid cyst located in the brain of a 7-year old child previously subjected to an invasive diagnosis and therapeutic procedures due to pleural empyema²⁵, endocarditis in an elderly patient with previous bioprosthetic aortic valve replacement²⁶, and osteomyelitis after traumatic injury (open long bone fracture)⁹. The latter calls attention to the potential ubiquitous nature of the *E. ramosum* spores, which, like other *Clostridium* species, have probably originated from the soil and entered the body through an open traumatic wound⁹.

E. ramosum, together with *Clostridium innoculum* and *Clostridium clostridioforme*, belongs to a unique RIC group of clostridia (abbreviation is derived from the initial letters of the names of the bacteria; R- *ramosum*, I- *innoculum*, C- *clostridioforme*), that are often misidentified or are not observed in clinical isolates by routine microbiological methods due to difficulties in distinguishing them from other anaerobic bacteria. The reason for is the inconsistent Gram staining pattern (usually negative at first), the typical formation of terminal spores that may be absent or difficult to identify, as well as atypical colony morphology^{6,22,27}. These factors probably explain the belief that infections

caused by *E. ramosum*, based on its correct identification as the only pathogen present in positive cultures, are underestimated in routine clinical practice. According to the ability of *E. ramosum* to produce acetic acid and ferment certain mono- and disaccharides as well as sugar alcohols⁵, in most cases covered by our review, this bacterium was identified by using conventional biochemical techniques, such as API test systems (BioMérieux SA, Marcy-l'Étoile, France). Although these phenotype-based tests are not entirely perfect in identifying *E. ramosum* in relation to other anaerobes²⁷, this review generally indicates their good reliability. However, the non-selectivity of this identification kit was reported to be related to different biochemical reactions used and their inability to differentiate *E. ramosum* from *Actinomyces israelii* with certainty; in this case, 16S rRNA gene sequencing was used as the gold standard for confirming that it was a *E. ramosum* isolate¹⁴. MALDI-TOF mass spectrometry was also used in some cases^{8,21} as a revolutionary, more attractive and accurate method for identifying bacteria based on their protein profile, but definitive confirmation of *E. ramosum* appears to require further use of bacterial genome analyzes⁸. As there is no routine laboratory identification of this bacterium, current state-of-the-art method, such as 16S rRNA gene sequencing, should be used whenever possible, either in combination or as the only diagnostic method to confirm *E. ramosum* isolates, especially in culture-negative infections.

As mentioned earlier, although antibiotics exhibiting bactericidal activity to *E. ramosum* are generally effective, either in monotherapy or in combination regimen, the recommended treatment for infections caused by this specific clostridium species has not yet been defined. Our review confirmed good *in vitro* susceptibility of *E. ramosum* mainly to metronidazole and two broad-spectrum beta-lactams plus beta-lactamase inhibitors (i.e. amoxicillin/clavulanate and piperacillin/tazobactam, respectively). In addition, another broad-spectrum beta-lactam (carbapenem) antibiotic, meropenem, showed high efficacy after frequent use, mostly without prior *in vitro* activity testing. This is not surprising since these drugs have long been recognized as the antimicrobial agents of choice or alternative antibiotics for the treatment of various anaerobic infections, including those caused by clostridial species²⁸. Favorable pharmacokinetic characteristics, especially wide distribution in almost all tissues, probably contribute to their efficacy in the treatment of the reported *E. ramosum* infections in different sites^{7,10,14,15,18,20,21,24,25}. Other potentially effective treatment options, depending on the type and severity of the infection, include ampicillin/sulbactam, imipenem, glycopeptides (vancomycin or teicoplanin) and chloramphenicol.

Previous studies showed that *E. ramosum* strains producing beta-lactamases exhibited resistance to penicillin in 20% of cases^{27,29}, so this antibiotic could not be recommended for the treatment of infections caused by *E. ramosum* due to the potential therapeutic failure. Similarly, the use of clindamycin or cephalosporins should also be avoided, because *E. ramosum* often shows variable susceptibility to these antibiotics, as other clostridial species do^{27,28}. Besides, the use of clindamycin in the treatment of severe invasive infections should not be practiced due to possible serious gastrointestinal side effects⁸. As mentioned previously, the antibiotic resistance in *E. ramosum* strains is not widespread. This anaerobic bacillus showed a high level resistance only to rifampin, aminoglycosides, fluoroquinolones and tetracyclines^{5,14}. However, certain tetracyclines, especially broad-spectrum minocycline¹⁸ or tigecycline²¹, might be possible treatment options for *E. ramosum* infections, when its *in vitro* susceptibility has been previously documented. Failure of antibiotic therapy despite the use of multiple antibiotics with proven *in vitro* activity on *E. ramosum* that can result in death or other serious complications is likely to be associated with uncontrolled progression of a severe underlying disease or with massive bacterial invasion associated with an extremely weak immune response of the host, as occurred in patients covered by this review^{9,17,20}. In addition, *E. ramosum* is often being isolated as a component of polymicrobial-mediated infections^{4,5,11-13} that are particularly difficult to treat and have unpredictable clinical outcomes.

This systematic review has the following shortcomings: (i) a relatively small number of reported cases with invasive infections caused by *E. ramosum* that was analyzed; (ii) 16S rRNA gene sequencing as the most accurate method for confirming *E. ramosum* in different isolates was used in only a few patients, implying a controversial reliability in terms of correct identification of this anaerobic bacterium; and (iii) in several analyzed reports, relevant information on the susceptibility of *E. ramosum* to antibiotics, as well as the description of all outcomes of the treatment of infections, were either missing or incomplete.

In conclusion, *E. ramosum* rarely plays a pathogenic role in causing serious invasive infections of various tissues in predisposed patients of any age, predominantly in those with significant level of immunosuppression. The 16S rRNA gene sequencing should be used independently of other phenotype-based methods and whenever possible, to accurately identify this bacterium. Metronidazole, a broad-spectrum beta-lactam with a beta-lactamase inhibitor and meropenem appear to be the antibiotics of choice that should be used in combination or as a monotherapy to treat

E. ramosum infections. Other antimicrobial agents, such as imipenem, glycopeptide antibiotics, chloramphenicol and tigecycline should only be used based on their *in vitro* activity findings.

ACKNOWLEDGMENTS

This study was partially financed by grant N° 175007, from the Serbian Ministry of Education, Science and Technological Development.

AUTHORS' CONTRIBUTIONS

MM designed the study; MM, SS, JM, MK, RZZ and MS performed the literature search and data analysis; SJ critically reviewed the work.

CONFLICT OF INTERESTS

The authors declare no conflict of interests.

REFERENCES

1. Parks DH, Chuvochina M, Waite DW, Skarhewski A, Chaumeil PA, Hugenholtz P. A standardized bacterial taxonomy based on genome phylogeny substantially revises the tree of life. *Nat Biotechnol.* 2018;36:996-1004.
2. Tally FP, Armfield AY, Dowell VR Jr, Kwok YY, Sutter VL, Finegold SM. Susceptibility of *Clostridium ramosum* to antimicrobial agents. *Antimicrob Agents Chemother.* 1974;5:589-93.
3. Kosowska K, Reinholdt J, Rasmussen LK, Sabat A, Potempa J, Kilian M, et al. The *Clostridium ramosum* IgA proteinase represents a novel type of metalloendopeptidase. *J Biol Chem.* 2002;277:11987-94.
4. Brook I. Clostridial infection in children. *J Med Microbiol.* 1995;42:78-82.
5. Forrester JD, Spain DA. *Clostridium ramosum* bacteremia: case report and literature review. *Surg Infect (Larchmt).* 2014;15:343-6.
6. Gajdacs M, Urbán E. The relevance of anaerobic bacteria in brain abscesses: a ten-year retrospective analysis (2008-2017). *Infect Dis (Lond).* 2019;51:779-81.
7. García-Jiménez A, Prim N, Crusi X, Benito N. Septic arthritis due to *Clostridium ramosum*. *Semin Arthritis Rheum.* 2016;45:617-20.
8. Zakhm F, Pillonel T, Brunel AS, Zambelli PY, Greub G, Croxatto A, et al. Molecular diagnosis and enrichment culture identified a septic pseudoarthrosis due to an infection with *Erysipelatoclostridium ramosum*. *Int J Infect Dis.* 2019;81:167-9.
9. Dahya V, Ramgopal M, Collin B, Robinson M. *Clostridium ramosum* Osteomyelitis in an immunocompetent patient after traumatic injury. *Infect Dis Clin Pract.* 2015;23:102-4.
10. Set R, Kandian S, Koppikar GV. *Clostridium ramosum* in a case of cerebellar abscess. *Indian J Med Microbiol.* 2001;19:149-50.
11. Nanda N, Voskuhl GW. Lung abscess caused by *Clostridium ramosum*. *J Okla State Med Assoc.* 2006;99:158-60.
12. Takano N, Yatabe MS, Yatabe J, Kato M, Sueoka D, Iguchi S, et al. Fatal Fournier's gangrene caused by *Clostridium ramosum* in a patient with central diabetes insipidus and insulin-dependent diabetes mellitus: a case report. *BMC Infect Dis.* 2018;18:363.
13. van der Vorm ER, von Rosenstiel IA, Spanjaard L, Dankert J. Gas gangrene in an immunocompromised girl due to a *Clostridium ramosum* infection. *Clin Infect Dis.* 1999;28:923-4.
14. Lavigne JP, Bouziges N, Sotto A, Leroux JL, Michaux-Charachon S. Spondylodiscitis due to *Clostridium ramosum* infection in an immunocompetent elderly patient. *J Clin Microbiol.* 2003;41:2223-6.
15. Alcalde-Vargas A, Trigo-Salado C, Leo Carnerero E, De-la-Cruz-Ramírez D, Herrera-Justiniano JM. Pseudomembranous colitis and bacteremia in an immune competent patient associated with a rare specie of *Clostridium* (*C. ramosum*). *Rev Esp Enferm Dig.* 2012;104:498-9.
16. Muakkassa WF, Mohanty PK, Kipreous B, Lee HM, Goldman MH. Left ventricular mass with septic (*Clostridium ramosum*) arterial emboli in a renal allograft patient: report of a case and review of the literature. *Transplant Proc.* 1983;15:1715-9.
17. Gerber JS, Berney-Meyer L, Segerer S. *Clostridium Ramosum*: a rare cause of peritoneal dialysis-related peritonitis. *Perit Dial Int.* 2018;38:231-2.
18. Kozaki S, Miyamoto S, Uchida K, Shuto T, Tanaka H, Wada T, et al. Infected thoracic aortic aneurysm caused by *Clostridium ramosum*: a case report. *J Cardiol Cases.* 2019;20:103-5.
19. Gajdacs M, Spengler G, Urbán E. Identification and antimicrobial susceptibility testing of anaerobic bacteria: Rubik's cube of clinical microbiology? *Antibiotics (Basel).* 2017;6:25.
20. Gollapudi LA, Narurkar R, Wang G, Dhand A. *Clostridium ramosum* (*C. ramosum*) bacteremia: single-center study. *Open Forum Infect Dis.* 2017;4 Suppl 1:S556.
21. Lim YK, Oh SM, Kweon OJ, Lee M. Two cases of bacteremias caused by *Clostridium ramosum*. *Ann Clin Microbiol.* 2015;18:98-101.
22. Mohandas R, Poduval RD, Unnikrishnan D. *Clostridium ramosum* bacteremia and osteomyelitis in a patient with infected pressure sores. *Infect Dis Clin Pract.* 2001;10:123-4.
23. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated *Clostridium difficile* infection. *Antimicrob Agents Chemother.* 2013;57:2326-32.

24. Brasha N, Abbas M, Gadeer A, Gadeer R, Ali A. Postpartum pyomyoma caused by *Clostridium Ramosum*: a case report. *Clin Experim Obstetr Gynecol.* 2018;45:636-40.
25. Turkoglu OF, Solaroglu I, Tun K, Beskonakli E, Taskin Y. Secondary infection of intracranial hydatid cyst with *Clostridium ramosum*. *Childs Nerv Syst.* 2005;21:1004-7.
26. Lorleac'h A, Cazanave C, Pereyre S, Kuli B, Neau D, Ragnaud JM. Une endocardite à *Clostridium ramosum*: premier cas décrit? *Med Malad Infect.* 2008;38:S146.
27. Alexander CJ, Citron DM, Brazier JS, Goldstein EJ. Identification and antimicrobial resistance patterns of clinical isolates of *Clostridium clostridioforme*, *Clostridium innocuum*, and *Clostridium ramosum* compared with those of clinical isolates of *Clostridium perfringens*. *J Clin Microbiol.* 1995;33:3209-15.
28. Brook I. Spectrum and treatment of anaerobic infections. *J Infect Chemother.* 2016;22:1-13.
29. Leal J, Gregson DB, Ross T, Church DL, Laupland KB. Epidemiology of *Clostridium* species bacteremia in Calgary, Canada, 2000-2006. *J Infect.* 2008;57:198-203.
30. Wikimedia Commons. Blank map political world territories. png. [cited 2021 Mar 3]. Available from: https://commons.wikimedia.org/wiki/File:Blank_map_political_world_territories.png